Intramuscular testosterone undecanoate for the treatment of male hypogonadism-review of recent data

Journal of Men's Health and Gender

Volumn 3, Issue 4, 2006, Pages 356-362

  Schubert, Markus ^a   Zitzmann, Michael ^b   Yassin, Aksam ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c Departments of Urology and Human Sexuality   (Germany)

Author keywords

Erectile dysfunction; Hypogonadism; Testosterone therapy; Testosterone undecanoate

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; BODY COMPOSITION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; HORMONE ACTION; HUMAN; HYPOGONADISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TESTOSTERONE BLOOD LEVEL;

EID: 33750825780     PISSN: 15718913     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmhg.2006.06.006     Document Type: Review

References (34)

1. Jockenhövel F. Male hypogonadism (2004), UNI-MED Science, Bremen
2. Mooradian A.D., Morley J.E., and Korenman S.G. Biological actions of androgens. Endocr Rev 8 1 (1987) 1-28
3. Alexandersen P., and Christiansen C. The aging male: testosterone deficiency and testosterone replacement. An up-date. Atherosclerosis 173 2 (2004) 157-169
4. von Eckardstein S., and Wu F.C. Testosterone and atherosclerosis. Growth Horm IGF Res 13 Suppl A (2003) S72-S84
5. Bhasin S., Bagatell C.J., Bremner W.J., et al. Issues in testosterone replacement in older men. J Clin Endocrinol Metab 83 10 (1998) 3435-3448
6. Behre H.M., and Nieschlag E. Comparative pharmacokinetics of testosterone esters. In: Nieschlag E., and Behre H.M. (Eds). Testosterone: Action, Deficiency, Substitution. 2nd edn. (1998), Springer-Verlag, Berlin 329-348
7. Meikle A.W., Mazer N.A., Moellmer J.F., et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 74 3 (1992) 623-628
8. Nieschlag E., Cuppers H.J., Wiegelmann W., and Wickings E.J. Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 7 3 (1976) 138-145
9. Nieschlag E., Swerdloff R., Behre H.M., et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 48 1 (2005) 1-4
10. Schurmeyer T., and Nieschlag E. Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. Int J Androl 7 3 (1984) 181-187
11. Schubert M., Minnemann T., Hubler D., et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89 11 (2004) 5429-5434
12. Nieschlag E., Buchter D., Von Eckardstein S., Abshagen K., Simoni M., and Behre H.M. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 51 6 (1999) 757-763
13. Behre H.M., Abshagen K., Oettel M., Hubler D., and Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140 5 (1999) 414-419
14. von Eckardstein S., and Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23 3 (2002) 419-425
15. Sommer F., Schwarzer U., Christoph A., Hübler D., Engelmann U., and Jockenhövel F. The effect of long-term testosterone replacement therapy on prostate specific antigen and prostate volume in hypogonadal men - results of a prospective study. Eur Urol 1 Suppl 1 (2002) 61 (Abstract 235)
16. Behre H.M., Nashan D., Hubert W., and Nieschlag E. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab 74 (1992) 84-90
17. Huebler D., Christoph A., Schubert M., et al. Effect of a new long-acting testosterone undecanoate (TU) formulation vs. testosterone enanthate (TE) for intramuscular androgen replacement therapy on sexual function and mood in hypogonadal men. Int J Impot Res 13 Suppl 1 (2001) S31
18. Huebler D., Schubert M., Minnemann A., et al. Effect of a new long-term treatment with a new sustained-action testosterone undecanoate (TU) formulation for intramuscular androgen replacement therapy on sexual function and mood in hypogonadal men. Int J Impot Res 14 Suppl 4 (2002) S51
19. Foresta C., Caretta N., Rossato M., Garolla A., and Ferlin A. Role of androgens in erectile function. J Urol 171 6 Pt 1 (2004) 2358-2362 quiz 2435
20. Morales A., Buvat J., Gooren L.J., et al. Endocrine aspects of sexual dysfunction in men. J Sex Med 1 1 (2004) 69-81
21. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol 15 1 (1997) 21-26
22. Azadzoi K.M., Kim N., Brown M.L., Goldstein I., Cohen R.A., and Saenz de Tejada I. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol 147 1 (1992) 220-225
23. Burnett A.L. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 16 Suppl 1 (2004) S15-S19
24. Traish A.M., Park K., Dhir V., Kim N.N., Moreland R.B., and Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinol 140 4 (1999) 1861-1868
25. Traish A.M., Munarriz R., O'Connell L., et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl 24 3 (2003) 381-387
26. Shen Z.J., Zhou X.L., Lu Y.L., and Chen Z.D. Effect of androgen deprivation on penile ultrastructure. Asian J Androl 5 1 (2003) 33-36
27. Traish A.M., Toselli P., Jeong S.J., and Kim N.N. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 26 2 (2005) 242-248
28. Yassin A.A., and Saad F. Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature. Andrologia 38 1 (2006) 34-37
29. ©) i.m. in hypogonadal patients. Abstract P045. In: International Congress of Andrology, 2005. Seoul: International Journal of Andrology; 2005.
30. Greenstein A., Mabjeesh N.J., Sofer M., Kaver I., Matzkin H., and Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed?. J Urol 173 2 (2005) 530-532
31. Shabsigh R., Kaufman J.M., Steidle C., and Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172 2 (2004) 658-663
32. Kalinchenko S.Y., Kozlov G.I., Gontcharov N.P., and Katsiya G.V. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 6 2 (2003) 94-99
33. Yassin A.A., Saad F., and Diede H.E. Kombinationstherapie bei erektiler Dysfunktion mit Testosteron und Tadalafil bei hypogonadalen Patienten, die auf Tadalafil als Monotherapie nicht ansprechen. Blickpunkt der Mann 2 1 (2003) 37-39
34. Zitzmann M, von Eckardstein S, Saad F, Nieschlag E. Long-term experience with injections of testosterone undecanoate for substitution therapy in hypogonadal men. In: 87th Annual Meeting of the Endocrine Society, 2005 June 4-7. San Diego, CA: Endocrine Society;2005. p. 306.